All In Biotech

Drug Trial Radar · NCT01099774

Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Last checked: Nov 19, 2026Latest source record: Apr 17, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 597 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

597

Actual

Start

May 1, 2010

Primary completion

Apr 29, 2011

Study completion Apr 29, 2011

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
First posted
Apr 8, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of bimatoprost 0.03% formulation B ophthalmic solution with LUMIGAN® (bimatoprost ophthalmic solution 0.03%) once daily for 12 weeks in patients with glaucoma or ocular hypertension

Conditions

  • Glaucoma
  • Ocular Hypertension

Interventions

  • Bimatoprost 0.03% Formulation B Ophthalmic SolutionDrug

    One drop administered in each eye, every evening, for 12 weeks

  • Bimatoprost 0.03% Ophthalmic SolutionDrug

    One drop administered in each eye, every evening, for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Week 12Time frame: Baseline, Week 12
  2. Average Eye IOP at Week 12Time frame: Baseline, Week 12
  3. Average Eye IOP at Week 6Time frame: Week 6
  4. Average Eye IOP at Week 2Time frame: Week 2

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Newport Beach, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.